← ANALYST RATINGS · TIPRANKS
Argenx Se (ARGX): analyst forecast and price target
Analyst consensus
Strong Buy14 Buy0 Hold0 Sell
Ratings of 14 analysts in the last 3 months · top analysts only12-month forecast
Based on 14 price targets given in the last 3 months, the average target is $1,199, the highest $1,400, the lowest $1,038. The average is +46.4% from the last price of $819.
Analyst ratings 25
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $1,355 → $1,356+0.1% | Buy | +65.5% | Assigned | 14.10.26on TipRanks 06:50 | +3.0%next day +3.1% | ↗ |
| David Nierengarten★★★★★★★★★★#297 · hits 55% · avg +23.0% | Wedbush | $1,150 → $1,130−1.7% | Buy | +37.9% | Reiterated | 13.10.26on TipRanks 09:25 | −1.2%next day +3.0% | ↗ |
| Leland Gershell★★★★★★★★★★#2332 · hits 40% · avg +6.2% | Oppenheimer | $1,100 → $1,038−5.6% | Buy | +26.7% | Reiterated | 12.10.26on TipRanks 08:55 | −1.5%next day −1.2% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $1,157 | Buy | +41.2% | Reiterated | 12.10.26on TipRanks 06:45 | −1.5%next day −1.2% | ↗ |
| Thomas Smith★★★★★★★★★★#45 · hits 57% · avg +51.1% | Leerink Partners | $1,115 | Buy | +36.1% | Reiterated | 09.10.26on TipRanks Oct 12 05:25 | +0.2%next day −1.5% · 5 days +1.3% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $1,141 → $933−18.2% | Buy | +13.9% | Reiterated | 09.10.26on TipRanks 19:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $1,156 → $933−19.3% | Buy | +13.9% | Reiterated | 09.10.26on TipRanks 19:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $1,141 → $905−20.7% | Buy | +10.5% | Reiterated | 09.10.26on TipRanks 19:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $1,146 → $909−20.7% | Buy | +11.0% | Reiterated | 09.10.26on TipRanks 19:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $1,171 → $946−19.2% | Buy | +15.5% | Reiterated | 09.10.26on TipRanks 19:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $1,176 → $941−20.0% | Buy | +14.9% | Reiterated | 09.10.26on TipRanks 19:05 | — | |
| Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% | Morgan Stanley | $1,250 → $1,140−8.8% | Buy | +39.2% | Reiterated | 09.10.26on TipRanks 09:45 | +0.2%next day −1.5% · 5 days +1.3% | ↗ |
| Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% | Evercore ISI | $1,175 → $1,078−8.3% | Buy | +31.6% | Reiterated | 09.10.26on TipRanks 08:20 | +0.2%next day −1.5% · 5 days +1.3% | ↗ |
| Colleen M. Kusy★★★★★★★★★★#12105 · hits 35% · avg −6.9% | Robert W. Baird | $932 → $823−11.7% | Hold | +0.5% | Assigned | 09.10.26on TipRanks 07:26 | +0.2%next day −1.5% · 5 days +1.3% | ↗ |
| Xian Deng★★★★★★★★★★#1289 · hits 61% · avg +16.6% | UBS | $1,400 | Buy | +70.9% | Reiterated | 08.10.26on TipRanks Oct 9 08:10 | −11.4%next day +0.2% · 5 days +3.7% | ↗ |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $1,100 | Buy | +34.3% | Reiterated | 08.10.26on TipRanks 21:45 | +0.2%next day −1.5% · 5 days +1.3% | ↗ |
| Douglas Tsao★★★★★★★★★★#207 · hits 56% · avg +24.3% | H.C. Wainwright | $1,202 | Buy | +46.7% | Reiterated | 08.10.26on TipRanks 11:06 | −11.4%next day +0.2% · 5 days +3.7% | ↗ |
| Alex Thompson CFA★★★★★★★★★★#60 · hits 73% · avg +50.6% | Stifel Nicolaus | $1,282 | Buy | +56.5% | Reiterated | 08.10.26on TipRanks 09:05 | −11.4%next day +0.2% · 5 days +3.7% | ↗ |
| Unknown Analyst | Jefferies | $1,215 | Buy | +48.3% | Reiterated | 15.09.26on TipRanks Sep 17 05:08 | −0.6%next day +0.9% · 5 days −4.0% | ↗ |
| Matt Phipps★★★★★★★★★★#2652 · hits 48% · avg +4.8% | William Blair | — | Buy | — | Reiterated | 02.09.26on TipRanks 11:45 | +2.2%next day −1.2% · 5 days −5.8% | ↗ |
| Danielle Brill★★★★★★★★★★#566 · hits 56% · avg +16.1% | Truist Financial | $1,030 → $1,095+6.3% | Buy | +33.7% | Reiterated | 18.08.26on TipRanks 07:30 | +1.2%next day +3.8% · 5 days +2.9% | ↗ |
| Jason Butler★★★★★★★★★★#412 · hits 51% · avg +18.3% | Citizens JMP | $932 → $1,200+28.8% | Buy | +46.5% | Reiterated | 18.08.26on TipRanks 05:50 | +1.2%next day +3.8% · 5 days +2.9% | ↗ |
| Samantha Semenkow★★★★★★★★★★#6889 · hits 47% · avg +0.7% | Citi | $1,203 → $1,301+8.1% | Buy | +58.8% | Reiterated | 18.08.26on TipRanks 02:50 | +1.2%next day +3.8% · 5 days +2.9% | ↗ |
| Yaron Werber★★★★★★★★★★#117 · hits 59% · avg +28.0% | TD Cowen | $1,146 → $1,353+18.1% | Buy | +65.2% | Reiterated | 17.08.26on TipRanks 13:30 | +16.5%next day +1.2% · 5 days +3.5% | ↗ |
| Allison Bratzel★★★★★★★★★★#171 · hits 64% · avg +41.9% | Piper Sandler | $1,075 → $1,215+13.0% | Buy | +48.3% | Reiterated | 17.08.26on TipRanks 07:20 | +16.5%next day +1.2% · 5 days +3.5% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $1,185 | Buy | +44.7% | Initiated | 04.08.26on TipRanks Aug 5 02:35 | −0.2%next day +3.0% · 5 days +2.5% | ↗ |
| James Gordon CFA★★★★★★★★★★#4717 · hits 61% · avg +4.7% | Barclays | $900 → $950+5.6% | Buy | +16.0% | Reiterated | 24.07.26on TipRanks 11:56 | −0.8%next day −3.2% · 5 days −8.1% | ↗ |
| Unknown Analyst | William O'Neil | — | Buy | — | Initiated | 08.06.26on TipRanks Jun 15 04:40 | −1.2%next day +0.5% · 5 days −1.9% | ↗ |
| Rajan Sharma★★★★★★★★★★#5820 · hits 52% · avg +1.9% | Goldman Sachs | $905 → $910+0.6% | Buy | +11.1% | Reiterated | 26.02.26on TipRanks Feb 27 05:55 | −5.0%next day −0.1% · 5 days −4.5% | ↗ |
| Richard Vosser★★★★★★★★★★#4454 · hits 49% · avg +2.0% | J.P. Morgan | $925 → $1,100+18.9% | Buy | +34.3% | Reiterated | 08.12.25on TipRanks 11:30 | +0.3%next day −1.2% · 5 days −5.1% | ↗ |
| Andy Chen★★★★★★★★★★#959 · hits 67% · avg +28.8% | Wolfe Research | — | Hold | — | Downgrade | 24.11.25on TipRanks 08:20 | −2.8%next day +0.3% · 5 days −1.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Argenx Se
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 08.10.26: target $1,183 at a price of $928 (+27.4%); now: $1,167 at $819 (+42.4%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 4 | 1 | 0 | 4 |
| Buy | 21 | 35 | 47 | 46 | 31 | 20 |
| Hold | 3 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 22.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $7.93 (from $6.38 to $10.79). Last quarter: $7.32.
Sales
Next quarter’s sales estimate — $1.7B (from $1.6B to $1.8B). Last quarter: $2.8B.
Best top-analyst consensus in the sector · Healthcare
About Argenx Se
- CEO: Karen Massey
- Employees: 1,863
- Laarderhoogtweg 25, Amsterdam, NH, 1101 EB, NL
- www.argenx.com
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, Ago
Data from the stock’s TipRanks forecast page, read 16 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗